Official Journal of the Italian Society of Orthopaedics and Traumatology
Author, year, ref. | Follow-up (months) | Type of treatment | Type of protocol | Samples (n) | Mean age (years) | Female gender (%) |
---|---|---|---|---|---|---|
Barthel et al. 2002 [17] | 12 | Meloxicam | 7.5Â mg daily / 14Â days | 24 | 65 | 42% |
Meloxicam | 15Â mg daily / 14Â days | 115 | 63 | 65% | ||
Indomethacin | 100Â mg daily / 14Â days | 111 | 63 | 64% | ||
Grohs et al. 2007 [7] | 12 | Rofecoxib | 25Â mg daily / 7Â days | 50 | 60 | 66% |
Indomethacin | 100Â mg per daily / 7Â days | 50 | 60 | 60% | ||
Legenstein et al. 2003 [34] | 6 | Indomethacin | 150Â mg daily / 12Â days | 58 | 68 | 59% |
Meloxicam | 7.5Â mg daily / 12Â days | 58 | 65 | 74% | ||
Romano et al. 1992 [35] | 24 | Indomethacin | 100Â mg per daily / 20Â days | 229 | 62 | 72% |
Celecoxib | 400Â mg daily / 20Â days | 147 | 59 | 74% | ||
Saudan et al. 2007 [25] | 3 | Celecoxib | 400Â mg daily / 10Â days | 117 | 69 | 53% |
Ibuprofen | 1200Â mg daily / 10Â days | 123 | 70 | 54% | ||
Van der Heide et al. 2004 [9] | 6 | Indomethacin | 150Â mg daily / 7Â days | 89 | 67 | 68% |
Meloxicam | 15Â mg daily / 7Â days | 92 | 67 | 68% | ||
Van der Heide et al. 2007 [36] | 12 | Indomethacin | 150Â mg daily / 7Â days | 89 | Â | 62% |
Rofecoxib | 50Â mg daily / 7Â days | 85 | Â | 62% | ||
Winkler et al. 2016 [4] | 6 | Diclofenac | 150Â mg daily / 9Â days | 44 | 61 | 45% |
Etoricoxib | 90Â mg daily / 9Â days | 45 | 60 | 46% |